Uremia

Summary

Uremia (MONDO:0007008) is a disease and 30 clinical trials. Top therapeutic interventions include ascorbic acid, basiliximab, and cysteine. A subtype of kidney failure — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uremia
Mondo ID	MONDO:0007008
EFO	EFO:1001226
MeSH	D014511
DOID	DOID:4676
SNOMED CT	44730006
UMLS	C0041948
MedGen	12008
MedDRA	10046369
Is cancer (heuristic)	no

Also known as: uremia of renal origin

Disease family

This is a subtype of kidney failure. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › kidney failure › uremia

Related subtypes (2): acute kidney injury, chronic renal failure syndrome

Subtypes (1): uremic neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cysteine.

Clinical trials & evidence

Clinical trials

Clinical trials: 30.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE4	7
PHASE2	2
PHASE1/PHASE2	2
PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06998732	PHASE4	NOT_YET_RECRUITING	BCD to Measure the ED95 of Remimazolam-Assisted Sedation in Arteriovenous Fistula Creation Surgery
NCT00317005	PHASE4	COMPLETED	Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events
NCT00388648	PHASE4	COMPLETED	Very Low Protein Diet or Dialysis in Uremic Elderly?
NCT00442819	PHASE4	COMPLETED	Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney
NCT00649298	PHASE4	COMPLETED	A Clinical Trial of IntensiVE Dialysis
NCT01356433	PHASE4	COMPLETED	Influence of Oral Vitamin C Supplement on the Inflammation Status in Dialysis Patients
NCT05750875	PHASE4	COMPLETED	Gabapentin Versus Loratadine in Uremic Pruritus
NCT01583309	PHASE3	COMPLETED	Effects of Convective Therapies in Dialysis Patients
NCT01267760	PHASE2	COMPLETED	Clinical and Biochemical Effects of Multipass Hemodialysis
NCT01408797	PHASE1/PHASE2	UNKNOWN	Clonal Deletion on Living-Relative Donor Kidney Transplantation
NCT02050139	PHASE2	COMPLETED	L-Cysteine in Peritoneal Dialysis
NCT02492490	PHASE1/PHASE2	UNKNOWN	Effect of SVF Derived MSC in DCD Renal Transplantation
NCT05386433	EARLY_PHASE1	UNKNOWN	Paxlovid in the Treatment of COVID-19 Patients With Uremia
NCT03629977	Not specified	RECRUITING	Timing of Renal Replacement Therapy in the Critically Ill Patients
NCT06233838	Not specified	RECRUITING	Multi-center Clinical Study on Hemoperfusion of KHA80
NCT07189741	Not specified	NOT_YET_RECRUITING	Dynamic Breath VOC Profiling as a Non-invasive Tool to Assess Hemodialysis Adequacy
NCT00375635	Not specified	UNKNOWN	Removal of Protein Bound Uremic Toxins by Modified Plasma Separation and Adsorption Combined With Hemodialysis
NCT00577967	Not specified	UNKNOWN	Gabapentin - A Solution to Uremic Pruritus?
NCT01391884	Not specified	COMPLETED	Elimination of Incretin Hormones in Patients With Severe Kidney Failure
NCT01766895	Not specified	UNKNOWN	Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan
NCT02266238	Not specified	UNKNOWN	Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial
NCT02446535	Not specified	UNKNOWN	Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?
NCT02606955	Not specified	UNKNOWN	Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test
NCT03416192	Not specified	WITHDRAWN	12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.
NCT03437538	Not specified	COMPLETED	Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter
NCT04768309	Not specified	COMPLETED	Impact of Intestinal Microbiota on Uremic Toxins Productions
NCT05076318	Not specified	COMPLETED	Dysregulated Urea-synthesis at Terminal Uremia
NCT05899283	Not specified	COMPLETED	A Comparative Study of Two Kinds of Hemodialysis Filters
NCT06875115	Not specified	COMPLETED	Evaluation of the Efficacy of Laser Acupuncture on Uremic Pruritus
NCT07086430	Not specified	COMPLETED	Independent Effects of Visceral Adipose Volume and Density on Patient Survival in Peritoneal Dialysis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ASCORBIC ACID	4	1
BASILIXIMAB	4	1
CYSTEINE	4	1
FOLIC ACID	4	1
LORATADINE	4	1
NIRMATRELVIR	4	1
REMIMAZOLAM	4	1